Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BVS · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortBioventus Inc. is profitable, generates cash and carries moderate debt, with revenue stable (−0.9% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 9.5% | 48/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 4.0% | 36/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 13.7% | 68/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 8.9% | 59/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.70× | 75/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.60× | 22/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 2.40× | 46/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.44 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 12.7% | 71/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 3.17× | 100/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 14.5% | 57/100 |
| Operating margin volatility | 16.8% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 3.5% | 36/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 431 | 512 | 512 | 573 | 568 |
| Cost of revenue | 128 | 181 | 184 | 185 | 180 |
| Gross profit | 303 | 331 | 328 | 388 | 388 |
| Research & development | 19 | 24 | 13 | 14 | 12 |
| Selling, general & admin | 254 | 332 | 304 | 344 | 314 |
| Operating income | 12 | (167) | (82) | (15) | 54 |
| Pre-tax income | 9.5 | (189) | (121) | (52) | 26 |
| Income tax | (2) | (44) | 0.1 | (5.3) | (1.6) |
| Net income | 19 | (159) | (156) | (36) | 23 |
| Diluted EPS | −$0.15 | −$2.59 | −$2.49 | −$0.56 | $0.33 |
| Diluted shares (millions) | 45 | 61 | 63 | 65 | 69 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
0.44 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 27, 2026 · Data updated Aug 5, 2026